Feeds:
Posts
Comments

Archive for the ‘Investor Relations’ Category

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of June 4– June 8, 2012

Biotechnology indices finished higher  with major US averages. Clinical updates at ASCO were in sector focus. For the week, the BTK advanced 2.44% to 1415.85, and the NBI rose 3.43% to 1283.53.

 

REGULATORY

Merck announced the FDA issued a CRL regarding the NDA for ridaforolimus in metastatic soft tissue or bone sarcoma. Merck rose 1.07% to $37.90 on Wednesday. Ariad Pharmaceuticals, which is partnered with Merck on ridaforolimus, gained 2.78% to $16.65.

GlaxoSmithKline and XenoPort announced the FDA approved Horizant ER Tablets in postherpetic neuralgia (PHN) in adults. Glaxo slipped 0.25% to $44.27 on Thursday, and XenoPort dropped 9.56%. (more…)

Read Full Post »

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of May 28– June 1, 2012

Declines in biotechnology indices exceeded those in major US averages. For the week, the BTK receded 5.85% to 1382.11, and the NBI fell 4.53% to 1240.98. Each finished at the lowest levels since mid-April.

 

REGULATORY

Janssen Therapeutics, a division of Janssen Products, announced the FDA issued a CRL for a sNDA for an 800mg tablet of PREZISTA. PREZISTA is approved for once-daily oral administration of 800mg — two 400mg tablets — for the treatment of HIV-1 in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations.

Exelixis announced on Wednesday it completed the filing of its rolling NDA with the FDA for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer. Exelixis slipped 0.65% to $4.59. (more…)

Read Full Post »

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of May 21– May 25, 2012

Biotechnology gains outpaced those in major US averages. For the week, the BTK rose 3.32% to 1467.97, and the NBI advanced 3.91% to 1299.90.

 

REGULATORY

Merck announced the FDA approved a labeling update for ISENTRESS (raltegravir) Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients. Merck fell 0.58% to $37.60 on Monday.

Vertex Pharmaceuticals announced on Friday the CHMP issued a positive opinion by consensus recommending the approval of KALYDECO for people with CF ages 6 and older who have at least one copy of the G551D mutation in the CF transmembrane conductance regulator gene. Vertex rose 1.19% to $64.85. (more…)

Read Full Post »

The Thomson Reuters Extel 2012 Investor Relations North America study has begun!

I invite you and your IR team to take part in the first Thomson Reuters Extel Investor Relations study for North America.

Voting runs until July 1st, 2012.

To take part –

Online at www.extelsurveys.com (Log in with your email address & your password; then click on the VOTE NOW button or

By email: please request an interactive PDF questionnaire which you can return to us by email or fax

Why take the survey?

Every company taking part will get a complimentary copy of the Executive Summary report, giving you the highlights on the key trends in IR, and what the buy-side and sell-side are really looking for from IR teams.

And one lucky winner will win a new Apple iPad!

I do hope you will be able to take part in the Survey, and please let me know at any time if you have questions or concerns.

Thank you and regards,

The Extel Team

extelsurveys@thomsonreuters.com

Read Full Post »

The Thomson Reuters Extel 2012 Investor Relations North America study has begun!

I invite you and your IR team to take part in the first Thomson Reuters Extel Investor Relations study for North America.

Voting runs from April 30th to May 25th, 2012.

To take part –

Online at www.extelsurveys.com (Log in with your email address & your password; then click on the VOTE NOW button or

By email: please request interactive PDF questionnaire which you can return to us by email or fax

Why take the survey?

Every company taking part will get a complimentary copy of the Executive Summary report, giving you the highlights on the key trends in IR, and what the buy-side and sell-side are really looking for from IR teams.

One lucky winner will win an iPad!

I do hope you will be able to take part in the Survey, and please let me know at any time if you have questions or concerns.

Thank you and regards,

 

Extel team

 

 Contact details:

 

extelsurveys@thomsonreuters.com

 

Tel. +44 (0) 20 7542 7700

 

Read Full Post »

“The future ain’t what it used to be” – Yogi Berra  

 What’s the market telling us?

According to the Thomson Reuters proprietary research team, of the 275 S&P 500 companies that have reported Q1 2012 earnings thus far, 72% have beat analysts’ expectations. While this number is considerably higher than the long-term average of 62%, share performance on earnings days has told a remarkably different story. With an average one-day share gain of 0.47% and individual stock fluctuation scattered anywhere between -29% to +52%, we have found that accounting for market expectations going into an event allows us to predict how a stock will perform post earnings release. By understanding the tools that investors utilize to predict market moves on scheduled corporate events, such as earnings releases, Investor Relations Officers (IRO’s) can gain insight to how the market is positioning. Therefore, this creates an opportunity to better prepare and cushion expectations leading up to the market moving events.

(more…)

Read Full Post »

Corporate communications professionals are publishing their own content every day: tweets, blog posts, email announcements, website copy, Facebook posts (to name just a few). Yet most still rely on a third party wire service to review and publish their regulatory and press releases—and they’re paying for it. Many are looking for an alternative to this time consuming and often costly process.

Constellation Brands—the world’s leading premium wine producer—has implemented such an alternative using a secure self-publishing tool from Thomson Reuters. They now have full control of their releases from start to finish and are reallocating the cost-savings toward other activities such as measurement.

“The Thomson Reuters release publishing solution helps us meet our SEC disclosure requirements through a secure process,” said Patty Yahn-Urlau, Vice President of  Investor Relations at Constellation Brands. 

Read the case study to learn more, and let us know how you’re optimizing your disclosure process.

Read Full Post »

The Investment Landscape in Asia

Accessing pools of capital in the Asia Pacific region is a topic that is of great interest to many investor relations teams in both North America and Western Europe.

In order to get a deeper understanding of the opportunity in Asia for Western companies the targeting team at Thomson Reuters pulled together some key data on the Asia Pacific investment opportunity.

We discussed some of the key findings from that analysis in our webinar today along with sharing experiences clients have had in meeting with investors in Asia and the view from some sell-side firms who have taken companies on the road to Asia.

Highlights from the webinar we hosted included:

•           The challenges Western companies face in attracting investors in Asia

•           The true investment opportunity in Asia

•           Key takeaways for IR officers looking to attract capital from Asia

For anyone who missed our webinar on the Investment Landscape in Asia, please watch the webinar and download the presentation at your convenience.

Read Full Post »

Stock market volatility and a slow economic recovery have led to the emergence of a new generation of activists. Some shareholders are focused on corporate governance issues such as increased transparency while others are dissident and interested in major changes.

Say on Pay

New regulation such as Dodd-Frank Wall Street Reform has provided investors with a voice at the annual meeting. Signed into law in July 2010, Dodd-Frank enables shareholders to vote to approve the compensation of senior executives.

Many investors believe that there’s a disconnect between pay & performance – high CEO pay despite underperforming stocks.   Not surprisingly, executive compensation and board-related issues, including withholding votes for Directors who are members of executive compensation committees, are the top concerns of shareholders. Other corporate governance issues include too much control and limited accountability.

Here are the key trends in say on pay:

  • According to data from Georgeson, for companies in the S&P 1500, there were 240 corporate governance proposals voted on in 2011, down from 342 in 2010 and 371 in 2009. Although very few shareholder proposals have passed, there have been a surprising number of votes against companies. The majority vote passes but 75% is considered a success.
  • In 2011, 157 companies failed to garner 70% of shareholder support.
  • According to our Thomson Reuters Asset4 data, Microsoft topped the global list of companies ranked highest for their corporate governance initiatives in 2011. Other companies recognized for their efforts included: Standard Life, Lend Lease Group, Procter & Gamble, Kraft Foods, ConAgra Foods and Duke Energy.

We expect that say on pay issues will remain in the forefront this year. A bearish  market with low valuations coupled with decreased tolerance for even short-periods of underperformance or perceived poor management can help foster an environment for activism, particularly in the U.S. and Canada. 

Trends in Activism

Turning to activism, although shareholders don’t run a company, they can exercise their rights as owners and influence the board of directors and management. There are two primary types of activists, those interested in governance matters (calSTRS) who tend to be long-term oriented and those who are decidedly more hostile & aggressive in their tactics to increase shareholder value (Icahn, Relational).

According to our Thomson ONE data, in 2011, there were nearly 300 instances of shareholder activism with board representation.  A seat on the board was at the top of activist demands. This demand has not changed thus far, in 2012, where there have been 16 instances of activism.

Top Factors that Attract Activists

Why do companies attract activist investors? Here are a few reasons we’ve derived from our data:

  • Undervalued companies – low P/E multiples vs. peers
  • Companies going through a major change: CEO/crisis/restructuring
  • Controversial CEO – High compensation, outspoken/aggressive comments
  • Underperformance – Multiple quarters of missed guidance
  • History of accounting irregularities/governance issues
  • High levels of cash/assets that can be easily monetized
  • Declining investor sentiment

Managing activist risk: Tips for IR officers

As shareholder activism and say on pay continue to be an on-going reality for many investor relations teams, here are recommendations for managing your activist risk:

  • Understand investor and activist concerns
  • Know your shareholder base and gather feedback

Take action – if your received less than 75% of votes, reach out to investors and understand their concerns to avoid a repeat 

For more information, please contact Lou Cordone at lou.cordone@thomsonreuters.com or Arzu Cevik at arzu.cevik@thomsonreuters.com.  Also watch our webinar on the topic.

Share your experience and best practices in managing activists or say on pay.

Read Full Post »

Just as governments worldwide are looking to Asia to be the engine of global economic growth, so many North American and European companies are hoping eagerly for Asian asset managers to take a position in their stock.  The Asian opportunity looms large with many Western companies deriving an increasing proportion of their operations and revenues from the region. 

And while there are heavy redemptions across much of the investment management industry in the U.S. and in Europe, Asia is experiencing at least modest inflows into its equity funds.  As a result, brokers’ corporate access teams are boosting their efforts to get Western companies to Asia to meet investors.

However, seizing the Asia opportunity presents real challenges.  IR practices data collected by Thomson Reuters shows that roadshows to Asia are still far from commonplace, with less than one in ten North American IR teams and only around a quarter of European IR teams stating they regularly visit investors in the region.  Companies are questioning whether it is in fact a worthwhile use of IR’s time given any roadshow to Asia would involve long journeys and a significant investment of precious management and senior IR resources.

To give insight and understanding on the Asian investor landscape, here are some helpful data points from our recent research and analysis of the region:

  • The asset base in Asia is significant. In fact, it is not far from the size of assets in Europe (US$7.8 trillion vs. $8.2 trillion). However, there are a number of vital differences:
  • The portion that is actively managed is very small. In North America, 71% of assets are managed on an active basis, ahead of Europe at just over half. However, in Asia that proportion falls to 28%, demonstrating that the pool of assets that an investor relations team could actually target and influence is a lot smaller than the headline asset number suggests.
  • Domestic bias is very strong. That pool is diminished even further when we consider the fact that the portion of assets that are invested outside of the region stands at less than 20%. So the addressable potential is a lot smaller than first meets the eye for a global company looking at doing a roadshow in Asia. But there is better news.

When looking at the proportion of assets that meet the criteria of being both actively managed and invested outside of Asia, Thomson Reuters data shows over 80% are located in just five locations  – China, Hong Kong, Tokyo, Singapore and Sydney. Moreover, within these locations the top 5 investment firms represent well over 50% of the active assets invested outside the region.

So, any company looking to do a roadshow in Asia can hit the majority of the addressable potential by just visiting a handful of institutions in each of the key money centres.

Many companies go to Asia attracted in part by the long-term investment horizon of many of the funds in the region. But low portfolio turnover is a double-edged sword for companies and also means institutions take longer to make decisions to initiate a position. A two week trip to Asia every 18 months will likely leave companies disappointed and questioning the value of their time there. Asian investors typically require regular and sustained communication before initiating a position.

So based on our analysis, here are our key takeaways for IR officers:

  • The Asia investor market is much smaller for an international company than it first appears
  • Companies with a commercial presence in Asia are better placed to attract Asian investment dollars
  • A very focused roadshow program makes the most sense
  • Asia is a long-term play for long-term investors

Interested in attracting capital from Asia?  Share your experience or let us know what additional questions you may have.  We’ll be hosting a webinar on the topic in early 2Q12.

Download our complimentary report on Targeting Investors in Asia Pac

For more information about Targeting, please contact James Tickner, james.tickner@thomsonreuters.com

Read Full Post »